Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
BioNTech SE
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
ToLymph Inc.
Neonc Technologies, Inc.
Pfizer
AstraZeneca
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
Amgen
Hackensack Meridian Health
Merck Sharp & Dohme LLC
Intergroupe Francophone de Cancerologie Thoracique
Eli Lilly and Company
Second Affiliated Hospital of Nanchang University
University of Illinois at Chicago
NRG Oncology
University of Utah
Abramson Cancer Center at Penn Medicine
Intergroupe Francophone de Cancerologie Thoracique
Fate Therapeutics
Shanghai Hengrui Pharmaceutical Co., Ltd.
Fundación GECP
IDEAYA Biosciences
BioNTech SE
Weill Medical College of Cornell University
Phanes Therapeutics
Nurix Therapeutics, Inc.
University of Alabama at Birmingham
First Affiliated Hospital of Zhejiang University
Shanghai Junshi Bioscience Co., Ltd.
Hospital Sultanah Bahiyah
Iovance Biotherapeutics, Inc.
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Stanford University
Fox Chase Cancer Center
Biotheus Inc.
Qilu Pharmaceutical Co., Ltd.